Navigation Links
FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients
Date:10/24/2013

RARITAN, N.J., Oct. 24, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously (19 to 0) to recommend approval of the investigational protease inhibitor simeprevir (TMC435) administered once daily as a 150 mg capsule with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis. The Advisory Committee recommended the approval of simeprevir based on analyses of data from clinical trials in patients who are treatment-naive or who have failed previous interferon-based therapy.

"We are pleased with the positive recommendation from the Advisory Committee for simeprevir and appreciate the rigorous review of our data," said Katia Boven, M.D., Medical Department Head, Infectious Diseases and Vaccines, Janssen. "It is our hope that the FDA will consider this recommendation and, upon completion of its review process, make simeprevir available to patients with genotype 1 chronic hepatitis C."

The FDA granted a Priority Review designation in May to the New Drug Application (NDA) filed by Janssen for simeprevir. Recommendations and findings from the Advisory Committee are based in part on efficacy and safety data from an extensive clinical development program for simeprevir and will be considered by the FDA in its review of the NDA for simeprevir, but the FDA is not required to follow them.  

The regulatory submission for simeprevir is supported in part by data from three pivotal Phase 3 studies – QUEST-1 and QUEST-2 in treatment-naive patients and PROMISE in patients who have relapsed after prior interferon-based treatment – as well as data from the Phase 2b ASPIRE study in prior non-responder patients. Janssen R&D Ireland presented data
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vaccinogen Names Dr. Benjamin Carson and Dr. Jan B. Vermorken to Medical Advisory Board
2. BSMA Expands Advisory Board to Advance BIOTECH SUPPLY CHAIN
3. Egenix, Inc. Appoints Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee
4. Boyd "Rainmaker" Melson, Professional Athlete and Advocate for Spinal Cord Injury Treatment, Signs on as Advisory Board Member of Store-A-Tooth™ Dental Stem Cell Banking
5. PennWells Strategies in Biophotonics Event Adds Two New Advisory Board Members
6. Dr. David R. Bassett Joins ActiGraph Scientific Advisory Board
7. Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board
8. Generex Confirms Conference Call with Members of the Antigen Express Scientific Advisory Board
9. Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
10. Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board
11. Hemostemix Announces Formation of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 2011 Jennerex, Inc., a private clinical-stage biotherapeutics ... first-in-class targeted oncolytic virus products for cancer, together ... enrollment has been initiated and the first patient ... trial called TRAVERSE.  The trial is evaluating the ...
... BRISBANE, Calif., Nov. 3, 2011 InterMune, Inc. (NASDAQ: ... for the third quarter and nine months ended September ... clinical development activities, including the launch of Esbriet® (pirfenidone) ... Executive Officer and President of InterMune said, "The third ...
... 3, 2011 Reportlinker.com announces that a new ... Global Biochip Markets: Microarrays ... INTRODUCTION  ... BCC,s goal for this study was to determine ...
Cached Biology Technology:Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 2Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 3Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 4Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 5Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 6InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 8Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Global Biochip Markets: Microarrays and Lab-on-a-Chip 5
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... anthrax detection cartridge developed at Sandia National Laboratories and ... easier, faster and cheaper. , Bacillus anthracis ... in soils all over the world and can cause ... animals. The bacteria can survive in harsh conditions for ... may occur through skin contact, inhalation of spores or ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... BIRMINGHAM, Ala. The U.S. Department of Energy (DOE) ... of Alabama at Birmingham (UAB) School of Engineering on ... the capture and permanent safe storage, or sequestration, of ... Southern Company, the parent company of Alabama Power. ...
... is publishing a special issue "Beyond the Origin: Charles ... of Species which was published 150 years ago in November ... Dr. Ulrich Kutschera, professor of plant physiology and evolutionary biology ... this special issue are available free of charge until 30 ...
... brilliance of butterfly wings has inspired a 3.2m, three-year ... fields of security, energy and the environment. The University ... signed a collaborative contract to develop new technologies based ... next three years a team of physicists from the ...
Cached Biology News:UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: